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The value of orally administered griseofulvin
as an effective antifungal agent has been ade-
quately documented (1,2,3). In the initial studies
with commercially available griseofulvin, it was
observed that, regardless of the amount of drug
administered, the blood levels were very low and
the amount excreted in the urine was quite small
(3). This phenomenon is probably due to the fact
that the drug is relatively insoluble in aqueous
fluids and that there is probably little absorption
from the gastrointestinal tract.
By an improved process of micronization, the
particle size of griseofulvin was decreased to
approximately one-third its original size. Serum
levels on patients treated with micronized griseo-
fulvin were approximately equivalent to con-
centration obtained with twice the dose of or-
dinary griseofulvin.
This study was initiated to determine whether
or not micronized griseofulvin is more effective in
clinical application than ordinary griseofulvin.
THE STUDY
The drug. Micronized griseofulvin (C17H1706C1)
is an odorless white thermostable powder. It has a
total surface area value at least three or more
times that of the common pharmaceutical grade.
It is prepared by a special dry milling procedure,
and is relatively insoluble in water and olive oil
but it is soluble in ethyl alcohol, carbowax 300,
chloroform, acetone, and butyl acetate. For
patient administration, it was dispensed in gelatin
capsules, each containing 125 mg. of micronized
griseofulvin.Patient selection. The clinical studies were
performed on ambulatory patients in the author's
private practice and the out-patient clinic at the
University Hospital.
Dosage schedule. Each adult patient, regardless
of age or weight, was given a total daily dose of 0.5
grams of micronized griseofulvin in four equally
divided doses. Initially, children were given
0.375 grams of micronized griseofulvin as a total
daily dose.
RESULTS
Tinea capitis. Thirty one patients with tinea
eapitis were treated with micronized griseofulvin.
Two of these had infections due to Micros porurn
canis and 29 to Micros porum audouini. Diminution
of fluorescence and new hair growth were observed
in all instances in the third week of continuous
treatment, and in 5 weeks the infection was clear.
No adverse reactions were encountered in this
group.
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Onychomycosis. Four patients with onychomy-
cosis were treated with orally administered
micronized griseofulvin. In all instances the
infection was due to Trichophyton rubrum. Each
patient received 0.5 grams of the drug in four
divided doses each day until treatment was com-
pleted. In all patients the fingernails began to
show improvement 3 to 4 weeks after initiation of
treatment and new fingernail growth was com-
plete within 5 to 6 months. The toenails showed
slight improvement at the end of 6 months of
continuous treatment but the results were not
striking.
Tinea cruris. Micronized griseofulvin, 0.5
grams per day in divided doses, was administered
to 5 patients who had tinea cruris due to
Trichophyton rubrum. Where itching was a major
factor, the symptom was relieved within 48 to 72
hours after initiation of treatment. Clinical
improvement became apparent in one week and in
all cases involution of lesions was complete in 4 to
6 weeks.
Tinea corporis. Nine patients who had tinea
corporis due to Trichophyton rubrum were treated
with micronized griseofulvin, 0.5 grams per day in
divided doses. The infection in these patients had
been present for periods ranging from 6 months to
20 years. Following administration of medication,
the itching subsided in 24 to 48 hours. Clinical
improvement was noted during the first week of
treatment and involution of lesions was complete
inS to 8 weeks. It became necessary to discontinue
administration of micronized griseofulvin to one
patient because of severe frontal headaches. When
the available commercial griseofulvin was ad-
ministered, the headache disappeared and when
the micronized griseofulvin was readministered
the headache recurred.
Toxicity. One patient complained of mild
diarrhea while receiving micronized griseofulvin
but it was not severe enough to necessitate cessa-
tion of the treatment. One patient had severe
frontal headaches whenever she took micronized
griseofulvin but did not have this reaction when
she received the commercial variety.
REMARKS
In the clinical studies performed with standard
griseofulvin (3, 4, 5), the results indicated that a
dose of less than 1 gram per day for adults was
inadequate and for children it was necessary to
use from 750 mg. to 1 gm. to achieve satisfactory
results (3, 4, 5). In the present study using micro-
nized griseofulvin, it is obvious that a satisfactory
clinical result can be obtained with a total daily
dose of 0.5 gms. of the drug, indicating that mg.
for mg. micronized griseofulvin has apparently
twice the efficacy of standard griseofulvin.
In the original study with griseofulvin, it was
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observed that oral administration of the drug did
not result in impressive levels in blood or urine
when considered in relation to the quantity given.
It was theorized that this might be due to the low
solubility of the agent in aqueous fluids and
limited absorption from the gastrointestinal
tract. A daily dose of 1 gm. of griseofulvin pro-
duced a concentration of 0.5 micrograms per ml. of
plasma. These studies were made with the Beck-
man Model DU spectrophotometer (3). The
concentrations obtained in this study varied
slightly but in no instance reached the level of one
microgram per ml. The studies performed with
micronized griseofulvin by Kraml and Dubuc
indicated that a dose of 0.5 gms would produce
serum levels "indistinguishable from those ob-
tained with 1 gm. of common pharmaceutical grade
griseofulvin." They also observed that 1.0 gm. of
micronized griseofulvin administered orally pro-
duced serum levels 1.7 times higher than an equal
dose of common grade griseofulvin (6).
Kraml and Dubuc reported (6) that their results
conclusively demonstrated that common phar-
maceutical grade griseofulvin when given orally is
only partly absorbed. In view of the fact that
micronized griseofulvin differs only from the
common grade by its particle size, they both
follow the same pathways of tissue deposition,
metabolism and urinary excretion. In order to
rationalize the two-fold increment of serum level,
they postulated it was due to increased absorption
from the gastrointestinal tract.
SUMMARY AND CONCLUSIONS
In this study, micronized griseofulvin has been
used effectively in the treatment of 49 patients
with superficial mycotic infections due to Micro-
sporum audouini, Micros porum canis and Tricho-
phyton rubrum.
The results obtained indicate that a 0.5 gm.
daily oral dose of micronized griseofulvin will
produce the same therapeutic results obtained by
the use of a 1 gm. daily dose of the standard
common grade griseofulvin.
Adverse reactions were minimal. One patient
complained of severe headache while taking
micronized griseofulvin but did not experience the
same reaction while taking the common variety.
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